These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

798 related items for PubMed ID: 1381201

  • 1. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.
    Posner MR, Elboim HS, Cannon T, Cavacini L, Hideshima T.
    AIDS Res Hum Retroviruses; 1992 May; 8(5):553-8. PubMed ID: 1381201
    [Abstract] [Full Text] [Related]

  • 2. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.
    Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA.
    J Immunol; 1991 Jun 15; 146(12):4325-32. PubMed ID: 1710248
    [Abstract] [Full Text] [Related]

  • 3. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.
    Posner MR, Cavacini LA, Emes CL, Power J, Byrn R.
    J Acquir Immune Defic Syndr (1988); 1993 Jan 15; 6(1):7-14. PubMed ID: 8417177
    [Abstract] [Full Text] [Related]

  • 4. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Matsushita S, Maeda H, Kimachi K, Eda Y, Maeda Y, Murakami T, Tokiyoshi S, Takatsuki K.
    AIDS Res Hum Retroviruses; 1992 Jun 15; 8(6):1107-15. PubMed ID: 1380258
    [Abstract] [Full Text] [Related]

  • 5. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F, Bergami PL, Duval M, Kuhrt D, Posner M, Cavacini L.
    AIDS Res Hum Retroviruses; 2003 Jul 15; 19(7):597-607. PubMed ID: 12908937
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120.
    Cavacini LA, Samore MH, Gambertoglio J, Jackson B, Duval M, Wisnewski A, Hammer S, Koziel C, Trapnell C, Posner MR.
    AIDS Res Hum Retroviruses; 1998 May 01; 14(7):545-50. PubMed ID: 9591708
    [Abstract] [Full Text] [Related]

  • 7. Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120.
    Ampol S, Pattanapanyasat K, Sutthent R, Permpikul P, Kantakamalakul W.
    AIDS Res Hum Retroviruses; 2012 Oct 01; 28(10):1250-8. PubMed ID: 22288892
    [Abstract] [Full Text] [Related]

  • 8. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
    Duchemin M, Khamassi M, Xu L, Tudor D, Bomsel M.
    Front Immunol; 2018 Oct 01; 9():244. PubMed ID: 29651286
    [Abstract] [Full Text] [Related]

  • 9. Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression.
    Cavacini LA, Emes CL, Power J, Underdahl J, Goldstein R, Mayer K, Posner MR.
    J Acquir Immune Defic Syndr (1988); 1993 Oct 01; 6(10):1093-102. PubMed ID: 7692037
    [Abstract] [Full Text] [Related]

  • 10. Primary cytotoxicity against the envelope glycoprotein of human immunodeficiency virus-1: evidence for antibody-dependent cellular cytotoxicity in vivo.
    Tanneau F, McChesney M, Lopez O, Sansonetti P, Montagnier L, Rivière Y.
    J Infect Dis; 1990 Oct 01; 162(4):837-43. PubMed ID: 1698205
    [Abstract] [Full Text] [Related]

  • 11. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
    Alsmadi O, Tilley SA.
    J Virol; 1998 Jan 01; 72(1):286-93. PubMed ID: 9420226
    [Abstract] [Full Text] [Related]

  • 12. Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization.
    Cavacini LA, Emes CL, Power J, Duval M, Posner MR.
    J Immunol; 1994 Mar 01; 152(5):2538-45. PubMed ID: 7510748
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
    Smith SA, Burton SL, Kilembe W, Lakhi S, Karita E, Price M, Allen S, Derdeyn CA.
    Front Immunol; 2018 Mar 01; 9():3163. PubMed ID: 30697215
    [Abstract] [Full Text] [Related]

  • 17. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects.
    Tyler DS, Stanley SD, Nastala CA, Austin AA, Bartlett JA, Stine KC, Lyerly HK, Bolognesi DP, Weinhold KJ.
    J Immunol; 1990 May 01; 144(9):3375-84. PubMed ID: 2329275
    [Abstract] [Full Text] [Related]

  • 18. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.
    Cavacini LA, Emes CL, Power J, Desharnais FD, Duval M, Montefiori D, Posner MR.
    J Immunol; 1995 Oct 01; 155(7):3638-44. PubMed ID: 7561063
    [Abstract] [Full Text] [Related]

  • 19. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.
    Bruel T, Guivel-Benhassine F, Lorin V, Lortat-Jacob H, Baleux F, Bourdic K, Noël N, Lambotte O, Mouquet H, Schwartz O.
    J Virol; 2017 Apr 15; 91(8):. PubMed ID: 28122982
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.